Schwarz PB, Peever JH. Dopamine triggers skeletal muscle tone by activating D 1 -like receptors on somatic motoneurons. J Neurophysiol 106: 1299 -1309, 2011. First published June 8, 2011 doi:10.1152/jn.00230.2011The dopamine system plays an integral role in motor physiology. Dopamine controls movement by modulation of higher-order motor centers (e.g., basal ganglia) but may also regulate movement by directly controlling motoneuron function. Even though dopamine cells synapse onto motoneurons, which themselves express dopamine receptors, it is unknown whether dopamine modulates skeletal muscle activity. Therefore, we aimed to determine whether changes in dopaminergic neurotransmission at a somatic motor pool affect motor outflow to skeletal muscles. We used microinjection, neuropharmacology, electrophysiology, and histology to determine whether manipulation of D 1 -and D 2 -like receptors on trigeminal motoneurons affects masseter and/or tensor palatini muscle tone in anesthetized rats. We found that apomorphine (a dopamine analog) activated trigeminal motoneurons and triggered a potent increase in both masseter and tensor palatini tone. This excitatory effect is mediated by D 1 -like receptors because specific D 1 -like receptor activation strengthened muscle tone and blockade of these receptors prevented dopamine-driven activation of motoneurons. Blockade of D 1 -like receptors alone had no detectable effect on basal masseter/tensor palatini tone, indicating the absence of a functional dopamine drive onto trigeminal motoneurons, at least during isoflurane anesthesia. Finally, we showed that D 2 -like receptors do not affect either trigeminal motoneuron function or masseter/tensor palatini muscle tone. Our results provide the first demonstration that dopamine can directly control movement by manipulating somatic motoneuron behavior and skeletal muscle tone.
DOPAMINE PLAYS an important role in both normal and pathological motor function. For example, dopamine cell loss underlies the motor deficits in Parkinson's disease (Riederer and Wuketich 1976) , and dopamine-targeting drugs are used to treat movement disorders such as restless legs syndrome (Clemens et al. 2006) . Lesion and stimulation studies in animals show that changes in dopamine cell activity affect motor behavior and movement (Galey et al. 1977; Piazza et al. 1989) . While dopamine plays a well-established role in extrapyramidal neural motor control, i.e., nigrostriatal pathway (Carlsson 1972) , it may also regulate movement by directly controlling motoneuron function.
Anatomic, electrophysiological, and pharmacological data indicate that dopamine may regulate movement by directly affecting motoneuron behavior. Dopamine neurons in A10 and A11 cell groups synapse onto neurons in the spinal ventral horn (Bjorklund and Skagerberg 1979; Qu et al. 2006; Ridet et al. 1992; Skagerberg et al. 1982) , and dopamine nerve terminals are located in cranial motor pools (Mascaro et al. 2005; Mong et al. 1988; Travers and Norgren 1983) . Presumptive motoneurons in both cranial and spinal motor pools express D 1 -and D 2 -like dopamine receptors (Dubois et al. 1986; Lazarov et al. 1998; Missale et al. 1998; Zhu et al. 2007 ). Dopamine release profiles in the vicinity of spinal motoneurons are correlated with changes in global motor activity (Gerin and Privat 1998) . Finally, and most importantly, dopamine directly influences the excitability of spinal motoneurons in vitro (Han et al. 2007; Han and Whelan 2009) .
Despite the evidence that dopamine can affect motoneuron physiology, it is unknown whether dopamine regulates muscle activity by directly controlling motoneuron function. Here we used microinjection, electrophysiology, neuropharmacology, and histology to determine whether changes in dopamine transmission at the trigeminal motor pool affect either masseter or tensor palatini muscle tone. We show that activation of D 1 -like receptors on (or near) trigeminal motoneurons potently strengthens masseter and tensor palatini muscle tone. Our results indicate that dopamine can directly modulate muscle tone by manipulating somatic motoneuron physiology.
MATERIALS AND METHODS
All experimental procedures were performed in accordance with the Canadian Council on Animal Care as well as with the approval of the University of Toronto Animal Care Committee. A total of 43 male Sprague-Dawley rats (age 9 -11 wk; mean weight 416 Ϯ 6 g) were used in these experiments.
Surgical Preparation
Animals were prepared for electrophysiological recording and microinjection as previously described (Schwarz et al. 2008) . Briefly, surgery was performed on spontaneously breathing animals anesthetized with 2% isoflurane. Effective depth of anesthesia was determined by abolition of the pedal withdrawal and blink reflexes. Animals were tracheostomized and intubated with a T-tube cannula. End-tidal CO 2 was sampled continuously with a fast response analyzer (VacuMed, Ventura, CA). Lactated Ringer solution was infused by a pump driver (1.5 ml/h; Harvard Apparatus, South Natick, MA) via a jugular vein catheter. Continuous blood pressure measurements were recorded with a pressure transducer (FHC, Bowdoin, ME) connected to a femoral artery catheter. Rectal temperature was monitored with a thermistor probe (Watlow, St. Louis, MO) and maintained at 37-38°C.
Electromyogram (EMG) activities of the masseter muscles and the tensor palatini served as an index of trigeminal motor output. Bipolar wire electrodes (Cooner Wire, Chatsworth, CA) were inserted into the left and right masseter muscles, and needle electrodes (Grass Technologies, West Warwick, RI) were inserted into the ventral surface of the soft palate to record tensor palatini muscle activity.
Rats were placed into a stereotaxic frame (David Kopf Instruments, Chatsworth, CA) and prepared for focal drug delivery as previously described (Schwarz et al. 2008) . A 25-gauge, 2-l microsyringe (Hamilton, Reno, NV) held by a stereotaxic micromanipulator (David Kopf Instruments) was inserted into the trigeminal motor pool (coordinates relative to bregma: 9.4 mm, 1.8 mm lateral, and 9.2 mm ventral).
Electrophysiological Recording
Masseter EMG signals were amplified 2,000 times with a Super-Z High-Impedance Head Stage and BMA-400 AC/DC Bioamplifier (CWE, Ardmore, PA), band-pass filtered between 30 Hz and 10 kHz, and sampled at 4.4 kHz. Respiratory EMG signals from the tensor palatini were amplified between 1,000 and 20,000 times on a NeuroLog System (Digitimer, Letchworth Garden City, UK), band-pass filtered between 60 Hz and 8 kHz on a graphic equalizer (Yamaha, Buena Park, CA), sampled at 4.4 kHz, and integrated in real time with a custom-built leaky integrator. EMG, blood pressure, and end-tidal CO 2 were monitored, digitized (Spike 2 Software, 1401 Interface, CED, Cambridge, UK), and stored on computer for off-line analysis.
Drugs
All drugs were dissolved in saline (0.9% NaCl). Glutamate receptor agonist. ␣-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid hydrobromide (AMPA, FW: 267.08 g/mol; Tocris, Ellisville, MO) was dissolved to a final stock concentration of 0.7 mM.
These drug concentrations have been used previously in microinjection or microinfusion studies (Exposito et al. 1999; Glaser et al. 2003; Harte and O'Connor 2004; Ikemoto 2003; Muralikrishnan and Ebadi 2001; Nakazawa and Ohno 1999; Savel'ev 2006; Umegaki et al. 2001 ). Apomorphine was selected as an appropriate nonselective dopamine agonist instead of dopamine because of its greater affinity for dopamine receptors (10-fold that of dopamine) and its slower catabolic inactivation in the synaptic cleft (Mantle et al. 1976; Weiner and Molinoff 1989) , rendering it more suitable for our pharmacological study.
Experimental Protocols
The goals of these experiments were to 1) determine whether dopamine activates trigeminal motoneurons and triggers masseter and tensor palatini EMG tone and 2) identify the receptor subtype that mediates dopaminergic modulation of motoneurons and muscle tone. To do this, the following general procedures were executed.
After microsyringe insertion and observation of an insertion-induced muscle activation (Fig. 1A) , rats were left to stabilize for 10 min or until EMG activity returned to baseline. A candidate drug (e.g., apomorphine) was then unilaterally microinjected onto the trigeminal motor pool over the course of 60 s. The volume of 0.2 l chosen is appropriate for minimizing diffusion to surrounding tissues (Myers 1966) . EMG activity was monitored and recorded before and for at least 15 min after microinjection. After injection the syringe was gently withdrawn, flushed thoroughly with filtered 70% ethanol and double-distilled water, and loaded with another compound.
No rat received more than two different drug applications, excluding AMPA control treatment. Dose-response experiments were performed in parallel groups of animals, whereby each motor pool was subjected to only one drug concentration. In experiments involving dopamine receptor blockade, rats were focally administered apomorphine, both alone and after pretreatment with either a D 1 -or D 2 -like receptor antagonist. Immediately after antagonist microinjection, microsyringes were reloaded with apomorphine and reinjected. The interval between antagonist injection and subsequent reinjection of apomorphine was ϳ20 min.
Control Experiments
Vehicle control. In one subset of rats, 0.2 l of saline vehicle was microinjected onto the trigeminal motor pool to rule out mechanically induced motoneuron activation due to fluid displacement.
Repeated microinjection. In another group of rats, 1 mM apomorphine was microinjected onto the trigeminal motor pool three consecutive times (separated by 15-min intervals) to verify that the motor pool could consistently respond to dopamine receptor activation. This procedure served as a control for experimental studies in which repeated drug injections would be made into the same motor pool (e.g., antagonist study).
AMPA microinjection. To serve as a positive control for accurate microsyringe placement and to ensure continued functionality of trigeminal motoneurons, 0.1 l of 0.7 mM AMPA was microinjected onto the trigeminal motor pool at the end of each experiment (Burgess et al. 2008) .
Histology. At the conclusion of experiments, rats were overdosed with isoflurane (5%) and asphyxiated until ventilation and cardiac activity ceased. Rats were immediately decapitated, and brains were dissected out and placed in chilled 4% paraformaldehyde in 0.1 M phosphate-buffered saline (PBS) at 4°C over 24 -72 h for fixation. Brains were then transferred to 30% sucrose in 0.1 M PBS for cryoprotection over several days until they sank in solution. Brains were subsequently cut on a sliding microtome (Leica Microsystems, Wetzlar, Germany) into 40-m coronal sections, mounted onto electrically charged slides (Fisher Scientific), and stained with Neutral Red (Sigma). The stained slides were visualized under an optical microscope (BX50W1 Olympus Microscope, Carsen Group, Markham, ON, Canada) in order to identify the microsyringe insertion tracks and the trigeminal motor pool. Images were photographed with a high-resolution digital camera (3.3 RTV Micro Publisher, QIMAGING, Burnaby, BC, Canada). The locations of insertion lesion tracks were plotted on standardized brain maps (Paxinos and Watson 2004) .
Data Analyses
Data analyses were performed both on-line and off-line with Spike 2 software (CED). Raw EMG signals were full-wave rectified and integrated on-line. Left and right masseter tonic EMG activity was partitioned into 10-ms epochs and averaged. A peak-detection analysis of the integrated tensor palatini EMG signal allowed for characterization of inspiratory activity; expiratory tensor palatini muscle tone was classified as EMG activity between bursts of inspiration (e.g., Fig. 2 
, B and C).
To identify basal muscle tone (i.e., baseline), EMG activity was averaged during the 60-s period immediately prior to microinjection. Duration of response to a drug treatment was designated as the period during which EMG activity exceeded and remained 2 standard devi-ations (SD) above the baseline mean value; wherever EMG activity dropped below this threshold but then immediately rose again, response duration was extended over this period until EMG activity dropped below threshold and was maintained at this level until the subsequent intervention. Amplitude of response to a microinjection was calculated as the mean EMG activity across the response duration, expressed in arbitrary units (AU). Latency to response was determined to be the period between onset of microinjection and the point when EMG activity increased 2 SD above baseline mean. Negative control (saline) injections were analyzed over the same response duration and latency as their corresponding drug injections. The percent change of EMG activity during drug intervention from baseline was calculated by dividing the difference of baseline and drug-evoked increase by baseline values and multiplying this factor by 100.
Statistical Analyses
The specific statistical tests used for analysis are included in RESULTS. Comparisons between two groups were made with either a paired t-test (parametric) or Wilcoxon's matched-pairs signranked tests (nonparametric), where appropriate. Comparisons between more than two treatments were made with a one-way ANOVA [repeated measures (RM), where appropriate]. StudentNewman-Keuls (SNK) and Dunn's tests (nonparametric) were used to determine statistical significance post hoc wherever ANOVA was performed. Dose-response comparisons were performed between groups (i.e., each motor pool received an injection of only 1 drug concentration). In experiments involving receptor blockade, comparisons were carried out within groups. Statistical analyses were performed electronically with Sigmastat (SPSS, Chicago, IL) and applied a critical two-tailed ␣ value of P Ͻ 0.05. Data are presented as means Ϯ SE.
RESULTS

Microsyringe Tips Were Located in Trigeminal Motor Pool
Three approaches were used to verify that microsyringe tips were located in the trigeminal motor pool. First, initial syringe insertion into the left motor pool caused a strong, but transient activation of both left masseter and tensor palatini EMG activity (n ϭ 26; paired t-tests, P Ͻ 0.001 for both muscles; Fig. 1A ). Syringe insertion had no effect on right masseter muscle tone (P ϭ 0.761; Fig. 1A ), indicating that it only activates motoneurons in the left motor pool. Second, to show that syringe tips were in the motor pool and that motoneurons were viable and able to respond to excitatory neurotransmission, we applied 0.7 mM AMPA onto trigeminal motoneurons at the end of each experiment (Burgess et al. 2008) . AMPA microinjection increased left masseter and tensor palatini muscle tone by 889 Ϯ 261% and 364 Ϯ 75%, respectively (n ϭ 26; signed-rank test, P Ͻ 0.001 for both muscles; Fig. 1, B and C) . Since both controls have been characterized in previous studies (Brooks and Peever 2008; Burgess et al. 2008; Schwarz et al. 2008) , only a subset of data traces were analyzed in this study (26 of 43 animals), and all experiments were monitored visually to ensure an insertion and AMPA-induced activation. Finally, we used postmortem histological analysis to visualize syringe lesion sites relative to the motor pool. In 47 of 48 cases, lesions were located within or at the border of the trigeminal nucleus (Fig. 1, D and E) . Data associated with the ectopic lesion site were excluded from analysis.
Dopamine Applied onto Trigeminal Motoneurons Triggers Increase in Masseter and Tensor Palatini Muscle Tone
To determine whether trigeminal motoneurons are excited by dopamine, we microinjected three different concentrations of apomorphine (1 dose per rat, i.e., 3 separate experimental groups) into the left trigeminal motor pool while monitoring left/right masseter and tensor palatini EMG activity. We found that apomorphine triggered a robust activation of both left masseter and tensor palatini muscles (Fig. 2) . Apomorphine dose-dependently strengthened masseter tone, increasing it by 286 Ϯ 86% (n ϭ 8; Dunn's post hoc test, P Ͻ 0.05) and 302 Ϯ 93% (n ϭ 18; P Ͻ 0.05) at 0.1 and 1 mM, respectively (Fig. 2, A  and D) . Drug response latencies and durations ranged from 2 to 438 s and from 21 to 792 s, respectively (Table 1) . Even though 0.01 mM apomorphine increased masseter tone by 139 Ϯ 64%, this effect was not statistically significant (n ϭ 8; P Ͼ 0.05; Fig. 2D ).
Unlike masseter muscles, which exhibit consistent levels of tone during anesthesia, tensor palatini muscles contract during inspiration and relax during expiration because they regulate airflow during breathing (Hairston and Sauerland 1981; McWhorter et al. 1999) . We analyzed the impact of apomorphine application on both inspiratory and expiratory tensor palatini activity. Apomorphine (1 mM) increased expiratory tensor palatini tone by 118 Ϯ 41% over baseline levels (n ϭ 17; ANOVA, SNK post hoc test, P ϭ 0.027; Fig. 2 , B and E) but had no effect on inspiratory activity (n ϭ 19; P ϭ 0.126; Fig.  2, C and F) . The latency and duration of this response ranged from 1 to 151 s and from 30 to 200 s, respectively (Table 1) . Lower apomorphine doses had no effect on either inspiratory (P Ͼ 0.05 at all doses) or expiratory (0.01 mM: P ϭ 0.609, n ϭ 6; 0.1 mM: P ϭ 0.510, n ϭ 6) (Fig. 2, E and F) EMG activity.
To demonstrate that microinjection per se had no effect on trigeminal motoneurons, we applied saline to the left motor pool. This intervention did not change either masseter or tensor palatini EMG levels (ANOVA, P Ͼ 0.05 for both muscles; Fig. 3, A and B) . To demonstrate that apomorphine effects on muscle tone were unilateral and mediated by activation of motoneurons in the left trigeminal motor pool, we quantified levels of right masseter muscle activity. Even though apomorphine increased left masseter tone (Fig. 2D) , this intervention had no effect on right masseter tone at any concentration (ANOVA, P ϭ 0.451; Fig. 3C ).
D 1 -Receptor Activation Excites Trigeminal Motoneurons and Heightens Masseter and Tensor Palatini Muscle Tone
Next, we aimed to determine whether excitatory D 1 -like receptors mediate dopaminergic activation of trigeminal motoneurons and subsequent motor outflow. We found that application of a D 1 -receptor agonist (SKF-38393) at the trigem- inal motor pool dose-dependently (1 concentration per rat, i.e., 3 separate experimental groups) increased both masseter and tensor palatini muscle tone (ANOVA, P Ͻ 0.05 for both muscles). Left masseter EMG tone increased by 120 Ϯ 67%, 135 Ϯ 84%, and 171 Ϯ 88% above baseline levels when 0.25 (n ϭ 5), 0.5 (n ϭ 5), and 1 (n ϭ 7) mM SKF-38393 were injected into the left motor pool, respectively (ANOVA, P Ͻ 0.05; Fig. 4A ). SKF-38393 microinjections (0.25, 0.5, and 1 mM) also heightened expiratory tensor palatini EMG tone by 16 Ϯ 9%, 21 Ϯ 15%, and 85 Ϯ 34%, although only the highest concentration (1 mM) triggered a statistically significant increase in muscle tone (ANOVA, Dunn's post hoc test, P Ͻ 0.05; Fig. 4B ). Inspiratory tensor palatini activity was unaffected by SKF-38393 application onto trigeminal motoneurons (ANOVA, P ϭ 0.706; data not shown).
D 1 -Receptor Activation Is Required for Dopaminergic Activation of Trigeminal Motoneurons
Here we wanted to determine whether D 1 -like receptors are required for apomorphine-induced activation of trigeminal motoneurons. However, before doing this we wanted to show that trigeminal motoneurons could respond to multiple drug interventions, since the following sets of experiments required repeated manipulations at the motor pool in the same animal. We found that the magnitude of the masseter response to three separate injections of apomorphine was statistically similar (n ϭ 4; RM ANOVA, P ϭ 0.653; Fig. 5A ). Similarly, three consecutive apomorphine injections consistently excited expiratory tensor palatini activity (P ϭ 0.104; Fig. 5B ).
Subsequently, we blocked D 1 -like receptors by pretreatment with a selective antagonist (SCH-23390) before exciting motoneurons with apomorphine. We found that apomorphine application (1 mM) alone triggered a robust, 186 Ϯ 78% increase in left masseter tone (n ϭ 12; RM ANOVA, SNK post hoc test, P Ͻ 0.05; Fig. 6A) ; however, this excitatory response was completely blocked when D 1 -like receptors were blocked by SCH-23390 pretreatment. Although SCH-23390 (1 mM) application on its own had no effect on left masseter tone (Fig.  6C) , it prevented the apomorphine-induced activation of masseter tone (SNK post hoc test, P Ͻ 0.05; Fig. 6A ). Blockade of D 1 -like receptors also abolished dopaminergic activation of expiratory tensor palatini muscle tone (n ϭ 12; RM ANOVA, SNK post hoc test, P ϭ 0.808; Fig. 6B ).
It should be emphasized that blockade of trigeminal D 1 -like receptors alone had no measurable effect on basal levels of masseter (RM ANOVA, SNK post hoc test, P Ͼ 0.05; Fig. 6C ) or expiratory tensor palatini (SNK post hoc test, P ϭ 0.821; Fig. 6D ) muscle tone, suggesting the lack of an endogenous dopaminergic drive onto trigeminal motoneurons during isoflurane anesthesia.
D 2 Receptors Do Not Mediate Dopaminergic Activation of Motoneurons
Finally, we wanted to determine whether D 2 -like receptors contribute to dopaminergic activation of motoneurons. We did this by blocking D 2 -like receptors by pretreatment with a selective antagonist (eticlopride) before activating motoneurons with apomorphine. We found that D 2 -like receptor blockade did not modulate dopaminergic facilitation of trigeminal motoneurons. Apomorphine application (1 mM) alone increased left masseter tone by 129 Ϯ 51% (n ϭ 8; RM ANOVA, SNK post hoc test, P ϭ 0.018; Fig. 7A ), and this excitatory response was not attenuated when D 2 -like receptors were antagonized by eticlopride pretreatment. Application of 0.1 mM eticlopride alone had no effect on left masseter tone (post hoc test, P Ͻ 0.05; Fig. 7C ), nor did it prevent apomorphine-induced activation of motoneurons and left masseter muscle tone (post hoc test, P Ͻ 0.05; Fig. 7A ). We also show that blockade of D 2 -like receptors did not abolish dopaminergic activation of expiratory tensor palatini muscle tone (n ϭ 8; RM ANOVA, SNK post hoc test, P Ͻ 0.05; Fig. 7B ). Eticlopride application itself had no effect on expiratory tensor palatini muscle tone (post hoc test, P Ͼ 0.05; Fig. 7D ).
To ensure that the absence of an effect was not due to incomplete D 2 -like receptor blockade, we also applied 20 mM eticlopride before giving apomorphine and found that this intervention did not prevent dopaminergic facilitation of motoneurons and hence increased masseter and tensor palatini muscle tone (RM ANOVA, P Ͻ 0.05 for both muscles; data not shown).
DISCUSSION
While dopamine plays a major role in motor regulation, this study is the first to demonstrate that it directly controls motor function by activating somatic motoneurons. Specifically, we show that exogenous application of dopamine onto trigeminal motoneurons heightens both masseter and tensor palatini muscle tone. We also show that D 1 -like, but not D 2 -like, receptors mediate the dopamine-driven activation of motoneurons. Our results shed new light on how the dopamine system may contribute to both normal and pathological control of motor function.
Technical Considerations
To mitigate the potential confounds that behavioral state (i.e., waking vs. sleep) exerts on dopaminergic transmission (Leger et al. 2010; Lu et al. 2006) , we used anesthetized instead of behaving rats. However, the dopamine system, like most transmitter systems (e.g., serotonin, norepinephrine, and GABA), is also affected by anesthetics. For example, isoflurane, the anesthetic used in these experiments, accelerates dopamine metabolism and can reduce its release within the striatum (Adachi et al. 2005 (Adachi et al. , 2008 . Isoflurane also markedly potentiates GABA A neurotransmission, which could in turn depress motoneuron excitability and compromise the effects of Fig. 6 . D 1 -like receptor activation is required for dopaminergic activation of trigeminal motoneurons. A: apomorphine (1 mM) microinjection onto trigeminal motoneurons increased masseter EMG tone (black bar); however, pretreatment with 1 mM SCH-23390 (D 1 -like receptor antagonist) in the same motor pool prevented dopamine-induced muscle activation (gray bar). B: dopamine-induced activation of tensor palatini tone (black bar) was also blocked by SCH-23390 pretreatment (gray bar). C and D: SCH-23390 application alone (black bars) had no effect on either masseter (C) or expiratory tensor palatini (D) muscle tone. All values are means Ϯ SE. *P Ͻ 0.05. neuromodulators such as dopamine (Franks and Lieb 1994) . Therefore, anesthetized rats are not ideal for studying how natural dopamine drives influence trigeminal motoneuron behavior and muscle tone. This limitation might explain why we did not detect an endogenous dopamine drive onto trigeminal motoneurons during isoflurane anesthesia (see Fig. 6 , C and D). Behaving rats would therefore be a more appropriate model for determining how endogenous dopamine drives influence motoneuron physiology.
However, the primary aim of these experiments was to determine whether dopamine receptor activation affects motoneuron function. No available evidence suggests that isoflurane directly impacts dopamine receptor function. Indeed, we show that D 1 -like receptor activation on (or near) motoneurons increases muscle tone. We suggest that dopamine has even stronger effects on motoneuron activity, but its excitatory potential is limited by isoflurane's suppression of general motoneuron excitability (Antognini et al. 1999; Franks and Lieb 1994) . This assertion is supported by preliminary data showing that dopamine potently activates trigeminal motoneurons and masseter tone during natural wakefulness in rats .
Another potential consideration is the anatomic and functional heterogeneity of the trigeminal motor nucleus. There are both excitatory and inhibitory interneurons within and around the motor pool that innervate trigeminal motoneurons (Moriyama 1987; Nozaki et al. 1993) . Dopamine could therefore modulate masseter muscle activity by affecting both trigeminal motoneurons and interneurons; however, we suggest that interneurons play a minimal role in mediating dopamine effects. Since interneurons send collaterals to both left and right trigeminal motor pools (McDavid et al. 2006; Ter Horst et al. 1990) , interneuron activation would be expected to trigger muscle tone in both left and right masseter muscles. However, we repeatedly showed that dopamine application at the left motor pool only activates left, and not right, masseter tone (Fig. 3C) . Therefore, we conclude that dopamine increases masseter tone by directly triggering trigeminal motoneuron excitation.
Dopamine Modulates Muscle Tone by Activating Motoneurons
Different lines of evidence indicate that dopamine indirectly influences motoneuron activity. First, dopamine neurons in the A11 cell group project to the spinal motor networks that trigger locomotion (Bjorklund and Skagerberg 1979) . Second, fictive locomotion is associated with an increase in dopamine concentrations around these motor circuits (Gerin and Privat 1998) . Third, selective ablation of A11 dopamine cells affects motor function in rats (Ondo et al. 2000; Zhao et al. 2007 ). Finally, dopamine application in the vicinity of spinal locomotor networks affects both motor reflexes and locomotor patterns in anesthetized cats and rats (Barasi and Roberts 1977; Barriere et al. 2004; Carp and Anderson 1982; Clemens et al. 2006; Gajendiran et al. 1996; Hasegawa et al. 1990; Maitra et al. 1992; Oksamitnyi and Tamarova 1987; Smith et al. 1995) . Dopamine may also influence spinal motoneuron function directly. For example, dopamine cells in both the A10 and A11 groups directly project to spinal motoneurons (Qu et al. 2006; Ridet et al. 1992) , which themselves express both D 1 -and D 2 -like dopamine receptors (Dubois et al. 1986; Zhu et al. 2007) . Importantly, in vitro experiments show that dopamine directly modulates spinal motoneuron excitability (Han et al. 2007 ).
Our work is the first to show that dopamine functions to increase skeletal muscle tone by activating somatic motoneurons. We show that application of apomorphine (a dopamine analog) onto trigeminal motoneurons triggers a short-latency activation of both masseter and tensor palatini muscle tone. Because the trigeminal motor area expresses D 1 -like receptors and receives dopaminergic innervation (Kitahama et al. 2000; Lazarov et al. 1998) , we assert that dopamine triggers muscle tone by directly exciting motoneurons. However, dopamine's excitatory effects could also be mediated by activation of trigeminal interneurons or premotoneurons contained within and in the vicinity of the trigeminal motor nucleus, which in turn would excite trigeminal motoneurons (Min et al. 2003) . Regardless of interpretation, our findings show that changes in dopaminergic transmission at the level of the motor pool modulate skeletal muscle tone. Our results are therefore the first to show that dopamine has the potential to influence muscle function in vivo by direct manipulation of motoneuron activity.
Dopamine Excites Motoneurons by a D 1 -Like Receptor Mechanism
Our results indicate that dopamine can trigger muscle tone by activating D 1 -like receptors on (or near) somatic motoneurons. Both anatomic and electrophysiological data support this finding. Immunohistochemical work shows that both spinal and cranial motoneurons express D 1 -like receptors (Dubois et al. 1986; Lazarov et al. 1998) ; however, no current evidence indicates that motoneurons also express D 2 -like receptors. In vitro data demonstrate that spinal motoneurons are directly excited by dopaminergic activation of D 1 -like, but not D 2 -like, receptors (Han et al. 2007) .
Dopamine may trigger muscle tone by accelerating motoneuron discharge rates. In vitro work indicates that dopamine increases spinal motoneuron discharge frequency by reducing the degree of afterhyperpolarization (Han et al. 2007 ). Reducing the afterhyperpolarization potential is an important mechanism for accelerating motoneuron firing frequency and increasing muscle activation (Gustafsson 1974) . Therefore, we hypothesize that dopamine strengthens muscle tone by activating D 1 -like receptors, which excite motoneurons, reduce afterhyperpolarization, and increase discharge frequency.
Dopamine may also facilitate motoneuron excitability indirectly by amplifying glutamatergic transmission (Han and Whelan 2009) . In vitro results show that activation of D 1 -like receptors can potentiate excitatory postsynaptic glutamatergic currents on neostriatal neurons (Umemiya and Raymond 1997) and boost AMPA-evoked currents in spinal motoneurons (Yang 2000) . However, we suggest that dopamine stimulates trigeminal motoneurons by directly acting on D 1 -like receptors. This assertion is based on the observation that dopamine does not facilitate inspiratory activation of tensor palatini muscle tone (see Fig. 2, E and F) . Because a glutamatergic mechanism relays inspiratory drive onto respiratory motoneurons (Funk et al. 1993; Steenland et al. 2006 Steenland et al. , 2008 Zuperku et al. 2008) , dopamine should presumably amplify this drive. However, since inspiratory activity remained unaffected, we conclude that dopamine primarily activates trigeminal motoneurons by a D 1 -like receptor mechanism.
Physiological and Clinical Significance
Dopamine neurons play a key role in motor physiology. For example, dopamine cell activation in the substantia nigra, A10, and A11 regions affects motor control (Ondo et al. 2000; Qu et al. 2006; Yahr et al. 1969) , and dopamine cell loss in Parkinson's disease impacts motor function (Hornykiewicz 1979) . Despite dopamine's established importance in motor physiology, our work is the first to show that it contributes to motor regulation by directly controlling motoneuron function in vivo.
We hypothesize that dopamine, like other neurotransmitters (e.g., glutamate and norepinephrine), regulates skeletal muscle tone by providing varying excitatory drive onto motoneurons (Burgess et al. 2008; Mir et al. 2006 ). An increase in dopamine drive would heighten muscle tone, whereas a decrease would weaken it. Studies using microdialysis and neural Fos expression show that dopamine neurons in the A10 and A11 cell groups are more active during wakefulness and least active during REM sleep (Leger et al. 2010; Lu et al. 2006; Skagerberg et al. 1982; Taepavarapruk et al. 2008) . Since these dopamine neurons also project to spinal motoneurons, they may strengthen muscle tone during waking and weaken it during sleep.
Determining whether dopamine normally activates motoneurons and muscle tone is of clinical relevance. For example, loss of a dopamine drive during sleep could weaken trigeminal motoneuron activation of masseter and tensor palatini muscles, which could reduce airway patency and lead to obstructive sleep apnea (OSA). This assertion could explain why OSA becomes more prevalent as dopamine cells are lost in Parkinson's disease (Maria et al. 2003) . Moreover, the stereotypical loss of facial expression and tone in Parkinson's disease (Bernheimer et al. 1973 ) could also result from reduced dopamine drive to trigeminal motoneurons controlling facial muscles.
